Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02754661
Other study ID # COVGIC20543
Secondary ID MA-213
Status Completed
Phase N/A
First received
Last updated
Start date September 2016
Est. completion date August 7, 2018

Study information

Verified date August 2019
Source Medtronic - MITG
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of this multicenter, prospective, randomized study is to assess the diagnostic yield of Colon Capsule Endoscopy (CCE) versus Computed Tomographic Colonography (CTC) in a screening population.


Description:

This is a multicenter, prospective, randomized study to evaluate the efficacy of CCE versus CTC in the identification of colonic polyps in a screening population.

Subjects will be enrolled at up to 20 clinical sites in the United States. Subjects who meet the eligibility criteria will be screened by the gastroenterology site for study participation at a baseline visit which will also include a blood test for renal function (eGFR), and will be evaluated on the randomized procedure day (CCE versus CTC) and again on the day of both the blinded and unblinded OC procedures. Telephone follow-ups will be conducted 5 - 9 days after the CCE/CTC procedure and 5 - 9 days after the unblinded OC procedure to assess subject well-being and capture any Adverse Events (AEs), regardless of relationship to the CCE, CTC, or Optical colonoscopy (OC) procedures.

All CCE RAPID® videos and CTC images will be evaluated by local and central readers. All study analyses will be based on central reader results for both CCE and CTC. Two sets of central readers will be utilized, one set for reading of the CCE RAPID® videos and one set for reading the CTC studies. Both groups of readers will be experts in the reading process for their respective procedures. Readers will provide a report of their findings to the sponsor within 2 weeks of capsule ingestion or CTC procedure in order to allow subjects to return within 5 weeks capsule ingestion or CTC procedure to undergo confirmatory OC. The first OC procedure will be performed with the clinician blinded to the CCE or CTC results. Immediately following this blinded procedure, the clinician will review the CCE or CTC results report provided by the sponsor from the central readers, and a second unblinded OC procedure will be performed if there are discrepancies between the CCE/CTC findings and OC.

Colonoscopy must not be performed by the same person who conducts the local CCE reading, or anyone who has reviewed CCE/CTC results for that subject.

Bowel preparation regimens for all three procedure types will be standardized across sites.


Recruitment information / eligibility

Status Completed
Enrollment 320
Est. completion date August 7, 2018
Est. primary completion date August 7, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 50 Years to 75 Years
Eligibility Inclusion Criteria:

1. Subject is between 50 and 75 years of age (for African Americans only, subject is between 45-75 years of age).

2. Subject is classified as average risk per the American Gastroenterological Association Guidelines on Colorectal Cancer Screening: Individuals without a personal or family history of CRC or adenomas, inflammatory bowel disease, or high-risk genetic syndromes.

3. Subject is willing and able to participate in the study procedures and to understand and sign the informed consent.

Exclusion Criteria:

1. Subject with history of colorectal cancer or adenoma (including those identified by computed tomography [CT], optical colonoscopy [OC[, sigmoidoscopy, etc.).

2. Subject with history of negative colonoscopy within 10 years, as these subjects would be defined as not requiring screening in this timeframe. For subjects with alternative screening methods, refer to applicable guidelines.

3. Subject with currently suspected or diagnosed with hematochezia, melena, iron deficiency with or without anemia, or any other rectal bleeding, including positive fecal occult blood test of any variety.

4. Subject with any current condition believed to have an increased risk of capsule retention such as suspected or known bowel obstruction, stricture, or fistula.

5. Subject with current dysphagia or any swallowing disorder.

6. Subject with current serious medical conditions that would increase the risk associated with CCE, CTC, or colonoscopy that are so severe that screening would have no benefit.

7. Subject with a cardiac pacemaker or other implanted electromedical device.

8. Subject expected to undergo MRI examination within 7 days after ingestion of the capsule.

9. Subject with clinical evidence of renal disease, including clinically significant laboratory abnormalities of renal function within the past 6 months, or at any time in the past if not tested within the last 6 months, defined as creatinine, blood urea nitrogen (BUN), and/or glomerular filtration rate (GFR) outside of the local laboratory reference range.

10. Subject with a diagnosis of gastroparesis or small bowel or large bowel dysmotility.

11. Subject with allergies or known contraindication to the medications or preparation agents used in the procedure as described in the relevant instructions for use.

12. Subject has an estimated life expectancy of less than 6 months.

13. Subject is considered to be part of a vulnerable population (e.g. prisoners or those without sufficient mental capacity).

14. Subject is pregnant, suspected pregnant, or is actively breast-feeding. Females of child-bearing potential will be required to provide either a urine pregnancy test or serum pregnancy test as part of the participant's standard of care regardless of their participation in the study (except for subjects who are surgically sterile or are post-menopausal for at least two years).

15. Subject has participated in an investigational drug or device research study within 30 days of enrollment that may interfere with the subject's safety or ability to participate in this study.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
COLON Capsule endoscopy

Computed Tomographic Colonography


Locations

Country Name City State
United States Asheville Gastroenterology Associates Asheville North Carolina
United States Loyola University Medical Center Chicago Illinois
United States Indiana University Hospital Indianapolis Indiana
United States Indianapolis Gastroenterology and Hepatology Indianapolis Indiana
United States Borland-Groover Clinic Jacksonville Florida
United States University of South Alabama Mobile Alabama
United States Columbia University New York New York
United States NYU New York New York
United States Thomas Jefferson University Philadelphia Pennsylvania
United States Mayo Clinic Rochester Rochester Minnesota
United States Clinical Research Professionals Saint Louis Missouri
United States Baystate Hospital Springfield Massachusetts
United States Virginia Gastroenterology institute Suffolk Virginia

Sponsors (1)

Lead Sponsor Collaborator
Medtronic - MITG

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With an Actionable Lesion on CCE vs. CTC Confirmed by Optical Colonoscopy Proportion of subjects shown to have an actionable lesion, defined as any polyp or mass lesion =6 mm.
Diagnostic yield of CCE/CTC will be calculated in relation to the confirmatory Optical colonoscopy results
5-6 weeks from randomized procedure
Secondary Sensitivity of CCE Versus CTC in the Detection of Polyps =6 mm Sensitivity (the percentage of patients with disease who test positive) assessed in relation to the confirmatory optical colonoscopy (OC) results on a "per subject" basis 5-6 weeks from randomized procedure
Secondary Specificity of CCE Versus CTC in the Detection of Polyps =6 mm Specificity (the percentage of patients without disease who test negative) assessed in relation to the confirmatory optical colonoscopy (OC) results on a "per subject" basis 5-6 weeks from randomized procedure
Secondary Predictive Value of a Positive Test (PPV) of CCE Versus CTC in the Detection of Polyps =6 mm Predictive value of a positive test (PPV) is the percentage of patients with positive tests who have disease assessed in relation to the confirmatory OC results on a "per subject" basis 5-6 weeks from randomized procedure
Secondary Predictive Value of a Negative (NPV) of CCE Versus CTC in the Detection of Polyps =6 mm Predictive value of a negative test (NPV) is the percentage of patients with negative tests who do not have disease, assessed in relation to the confirmatory OC results on a "per subject" basis. 5-6 weeks from randomized procedure
See also
  Status Clinical Trial Phase
Recruiting NCT05929820 - Impact of Protect Your Colon™ on CRC Screening N/A
Completed NCT00955344 - Increasing Primary Care Physician Colorectal Cancer Screening Rates N/A
Completed NCT01141114 - Study of Patient Navigation to Promote Colon Cancer Screening N/A
Completed NCT00503737 - Pilot Study of the National Colorectal Cancer Roundtable Toolbox (NCCRT) to Increase Colorectal Cancer Screening Rates N/A
Completed NCT01250015 - Does Numerical And Pictorial Information On Risk And Benefit Affects The Uptake Of Colorectal Cancer Screening? N/A
Completed NCT04746469 - Using Behavioral Science to Improve Colorectal Cancer Screening Rates With Mailed FIT Kits N/A
Completed NCT03208283 - Evaluation of the Impact of Water Method During Insertion Phase of Flexible Sigmoidoscopy in Training N/A
Not yet recruiting NCT03974542 - Telephone Outreach by Navigators to Improve Repeat Fecal Occult Blood Testing N/A
Completed NCT03176082 - Mailed Reminders Plus Fecal Immunochemical Testing N/A
Completed NCT01210235 - FLU-FIT Program at Kaiser Permanente Northern California N/A
Completed NCT00793455 - Outreach for Patients With Uncompleted Colorectal Cancer Screening Orders N/A
Completed NCT01099826 - Increasing Colorectal Cancer (CRC) Screening In Primary Care N/A
Active, not recruiting NCT04631692 - Evaluating a Health Literacy Intervention to Improve Colorectal Cancer Screening in Underserved Areas N/A
Completed NCT03225560 - Smart Phone App for COLOnoscopic PREParation N/A
Completed NCT01054924 - Performance Study of the Invendo C20 Colonoscope System in Colorectal Cancer Screening N/A
Completed NCT00148226 - ICIBS Trial - Improving Patient Information About Bowel Cancer Screening - a Decision Aid Trial Phase 2
Completed NCT04131946 - Cancer Screening; Access; Awareness; Navigation N/A
Recruiting NCT05785780 - Aim 3, Optimizing CRC Screening in Patients With Diabetes in Safety-net Primary Care Settings N/A
Completed NCT04237883 - Primary Care Clinical Excellence Incentive Study N/A
Not yet recruiting NCT06333392 - Total Underwater Colonoscopy (TUC) for Improved Colorectal Cancer Screening: A Randomized Controlled Trial N/A